Lilly Wins Appeal Upholding Patent on Alimta Cancer Drug (1)

摘要

Eli Lilly & Co. won an appeals court ruling that upholds the validity of a patent on its lung-cancer drug Alimta and helps keep generic versions of the medicine off the market until May 2022.The U.S. Court of Appeals for the Federal Circuit affirmed a Patent Trial and Appeal Board decision that rejected invalidity arguments raised by generic-drug makers, including Mylan NV, that sought to sell lower-cost versions of the drug.